Glooko said yesterday that it inked deals with Dexcom (NSDQ:DXCM) and Insulet (NSDQ:PODD) to supply device data from both companies to its diabetes management platform.
Glooko’s platform will now integrate Dexcom’s continuous glucose monitoring systems and Insulet’s OmniPod insulin management systems in a new version of the platform that’s slated for a summer release, the Palo Alto, Calif.-based company said.
“Now OmniPod patients will have the ability to view their insulin delivery, blood glucose and CGM data together. Patients will have access to data that will allow them to take full advantage of the clinical benefits that the OmniPod system provides while still providing the freedom of the unique, tubeless insulin delivery system. This collaboration furthers our shared vision of helping to make life with diabetes easier by providing greater access to the data people living with diabetes need to make smart and effective decisions to realize better control,” Insulet CEO Patrick Sullivan said in prepared remarks.
“We are pleased to be partnering with Glooko to add Dexcom CGM data to their comprehensive diabetes management platform. We believe that Glooko’s platform, which accesses Dexcom data through our ‘open architecture,’ can be a very meaningful tool for our patients to manage their diabetes,” added Dexcom CEO Kevin Sayer.
Glooko’s platform is designed to integrate data from more than 30 blood glucose monitors and other wearable and biometric devices with either an Apple (NSDQ:AAPL) iPhone or Google (NSDQ:GOOG) Android application. Food intake, medication and insulin dosage can also be recorded to provide context around changes in their blood glucose readings, the company added.
Data from meters and devices is sent to Glooko’s cloud-based Population Tracker, where patients and providers alike can view and analyze the data, and make decisions about interventions and treatments, Glooko said.
“Digital health data integration will have a significant impact on the clinical care we provide for people with diabetes. Our work with Glooko in creating the Joslin HypoMap powered by Glooko and Glooko continuing to add in device data and reports that synthesize information to provide clinically significant insights not present on currently-available data downloads will help more patients to realize the benefits of CGM and pump therapy, and will help clinicians provide more efficient and effective care,” Dr. Howard Wolpert of Boston’s Joslin Diabetes Center said in a prepared statement.
In March, Glooko closed a $16.5 million Series B round that included new investors Medtronic (NYSE:MDT), Canaan Partners and existing backers The Social + Capital Partnership and Samsung. Proceeds were slated to expand the company’s reach to insulin pumps, CGM devices and the integration of personalized predictive algorithms.